The Moderna pharmaceutical company announced that it begin clinical trials in the second phase of its study of a booster dose of its specific vaccine to combat the omicron variant of COVID-19.
In a statement, Moderna announced they begin clinical trials of the vaccine. They explained that the second phase of the study would include, on the one hand, about 300 participants who have already received two doses of the vaccine. And, on the other hand, another 300 subjects with the full schedule and a booster dose.
On the other hand, on the current vaccine’s effectiveness, Moderna indicated that according to a study. The neutralization of omicron six months after the third dose of 50 micrograms of the mRNA-1273 vaccine reduced but remained palpable in all participants in the test.
The chief executive of the pharmaceutical company, Stéphane Bancel, stressed that we reassurance by the persistence of antibodies against omicron six months after the currently authorized booster of 50 micrograms of mRNA-1273. He highlighted the importance of a booster specifically targeting omicron for the long-term threat evidenced by the variant of evading immune defenses.
According to data published by medico print media, 29 days after receiving the Moderna COVID-19 booster, there was a 6.3-fold decline in the neutralization of the omicron variant relative to its maximum capacity. However, we still detected antibodies in all participants.
This neutralization only dropped 2.3 times when it arrived at the original strain of the virus.
Other Companies Begin Clinical Trails Like Moderna on vaccine to against Omicron variant.
Pharmaceutical companies Pfizer and BioNTech announced the start of a clinical trial of a modified COVID-19 vaccine that can protect against the omicron variant of the coronavirus.
The statement from these two firms indicates that the study’s initial results, which will include 1,420 volunteers aged between 18 and 55, are expected to be available in the first half of this year.
Pfizer said in a message that they continue to have an open dialogue with health authorities about an updated vaccine and ongoing data on the currently available vaccine, including what authorities require.